查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1941548

生物相似药市场规模、份额和趋势分析报告：按药物类别、适应症、最终用途、地区和细分市场预测（2026-2033 年）

Biosimilars Market Size, Share & Trends Analysis Report By Drug Class, By Indication, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

生物相似药市场概述

2025年全球生物相似药市场规模估计为395.9亿美元，预计2033年将达到1,515.8亿美元。

预计从 2026 年到 2033 年，该市场将以 18.44% 的复合年增长率成长。生物相似药的成本效益和全球慢性病盛行率的不断上升是推动市场成长的主要因素。

由于生物相似药的研发相对容易，与新型生物製药相比，其研发投入较少，却能达到类似的临床疗效，因此市场持续成长。更短的研发週期和更高的生产效率意味着更低的生产成本，使製造商能够提供具有竞争力的价格和可观的利润率。随着已开发市场和新兴市场对高性价比生物製药疗法的需求不断增长，製造商正日益将策略重点转向生物相似药，以提高其产品组合的盈利。虽然生物相似药在辅料和製剂成分方面可能存在细微差异，但其评估标准是与参考生物製药在安全性、纯度和疗效方面不存在具有临床意义的差异，这支持了生物相似药在各个治疗领域的广泛应用。

法规结构在建立信任和加速市场渗透方面发挥核心作用。美国食品药物管理局(FDA) 要求生物相似药申请人通过详细的分析表征、药物动力学比较以及必要的临床证据，证明其产品与参考生物製药具有高度相似性。这些监管流程旨在确保病患安全，同时避免不必要的临床试验重复，从而降低研发风险和成本。这种严格而有效率的核准流程增强了医生和支付方对生物相似药的信任，有助于其在肿瘤学、免疫学和慢性病管理领域获得市场份额。

2025年一个显着的商业案例印证了这一趋势，即安进公司在美国推出的Weslana，它是Stelara的参考生物类似药，自体免疫疾病。此次上市标誌着高价值免疫学生物类似药发展的重要里程碑，也展现了安进公司在复杂的单株抗体领域竞争的能力。 Weslana的上市预计将改善皮肤病学和胃肠病学治疗的经济效益，同时加剧Ustekinumab市场的价格竞争，从而推动2025年生物相似药整体收入的成长。

监管核准的增加和投资活动的活性化进一步凸显了市场的成熟度。近年来，美国FDA已核准了多种肿瘤生物类似药，这些药物已成功商业性，并持续重塑市场竞争格局。同时，各药厂也加大研发投入，以强化其未来的产品线。例如，百康生物製药公司（Biocon Biologics）宣布计划增加研发支出，以扩大其生物相似药产品组合，反映出该公司对整个产业长期需求的信心。总而言之，这些进展凸显了生物相似药研发和商业化的持续繁荣，为预测期内市场的稳定成长奠定了基础。

目录

第一章调查方法和范围

第二章执行摘要

第三章 生物相似药市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析

第四章 生物相似药市场：依药物类别分類的商业分析

  • 按药物类别分類的市场份额（2025 年和 2033 年）
  • 按药物类别分類的市场规模、预测和趋势分析（2021-2033 年）
  • 单株抗体（mAbs）
  • 生长因子和造血因子
  • 胰岛素及其类似物
  • 骨质疏鬆症/骨骼代谢药物
  • 其他的

第五章 生物相似药市场：依适应症分類的业务分析

  • 按适应症分類的市场份额（2025 年和 2033 年）
  • 按适应症分類的市场规模、预测和趋势分析（2021-2033 年）
  • 自体免疫疾病（类风湿性关节炎、发炎性肠道疾病、干癣、僵直性脊椎炎）
  • 肿瘤科（乳癌、结肠癌、淋巴瘤、肺癌、胃癌）
  • 糖尿病（1 型和 2 型）
  • 眼科疾病（湿性老龄化黄斑部病变、糖尿病黄斑部水肿、视网膜静脉阻塞）
  • 血液疾病/罕见血液疾病
  • 其他的

第六章：生物相似药市场：依最终用途分類的业务分析

  • 按最终用途分類的市场份额（2025 年和 2033 年）
  • 按最终用途分類的市场规模、预测和趋势分析（2021年至2033年）
  • 医院
  • 专科药房
  • 线上和零售通路

第七章 生物相似药市场：区域估算与趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Amgen Inc
    • F Hoffman-La Roche Ltd.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Samsung Biopis
    • Biocon
    • Viatris Inc.
    • Celltrion Healthcare Co., Ltd.
    • AbbVie Inc.
Product Code: 978-1-68038-916-6

Biosimilars Market Summary

The global biosimilars market size was estimated at USD 39.59 billion in 2025 and is projected to reach USD 151.58 billion by 2033, growing at a CAGR of 18.44% from 2026 to 2033. The cost-effectiveness of biosimilar drugs and the prevalence of chronic disorders globally are major factors contributing to market growth.

The market continues to gain momentum as these products are comparatively easier to develop than novel biologics, requiring lower research and development investment while delivering comparable clinical outcomes. Reduced development timelines and manufacturing efficiencies translate into lower production costs, enabling competitive pricing and attractive margins for manufacturers. As demand for cost-effective biologic therapies rises across both developed and emerging markets, producers are increasingly shifting strategic focus toward biosimilars to enhance portfolio profitability. Although biosimilars may exhibit minor differences in excipients or formulation components, they are evaluated to ensure no clinically meaningful differences from reference biologics in terms of safety, purity, and efficacy, supporting their broader adoption across therapeutic areas.

Regulatory frameworks play a central role in building confidence and accelerating market uptake. The U.S. Food and Drug Administration requires biosimilar applicants to demonstrate high similarity to the reference biologic through extensive analytical characterization, pharmacokinetic comparability, and clinical evidence where required. These regulatory pathways are designed to ensure patient safety while avoiding unnecessary duplication of clinical trials, thereby reducing development risk and cost. Such stringent yet efficient approval processes have strengthened physician and payer trust in biosimilars, contributing to expanding market share in oncology, immunology, and chronic disease management.

A notable 2025 commercial instance reinforcing this trend is the U.S. launch of Wezlana by Amgen, a biosimilar referencing Stelara for autoimmune indications. This launch marked a significant milestone in high-value immunology biosimilars, demonstrating manufacturers' ability to compete in complex monoclonal antibody segments. The entry of Wezlana is expected to improve treatment affordability in dermatology and gastroenterology while intensifying price competition within the ustekinumab market, thereby supporting overall biosimilars revenue growth in 2025.

Growing regulatory approvals and investment activity further illustrate the market's maturity. The U.S. FDA approved multiple oncology-related biosimilars in recent years, translating into commercial launches that continue to shape the competitive landscape. In parallel, manufacturers are scaling research and development investments to strengthen future pipelines. For instance, Biocon Biologics announced plans to increase R&D spending to advance its biosimilar portfolio, reflecting industry-wide confidence in long-term demand. Collectively, these developments highlight a sustained boom in biosimilar development and commercialization, positioning the market for steady growth over the forecast period.

Global Biosimilars Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biosimilars market report based on drug class, indication, end use, and region:

  • Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
  • Monoclonal Antibodies (mAbs)
  • Growth Factors & Hematopoietic Agents
  • Insulin & Analogues
  • Osteoporosis / Bone Metabolism Agents
  • Others
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
  • Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
  • Diabetes Mellitus (Type 1 & Type 2)
  • Ophthalmic Disorders (Wet AMD, DME, RVO)
  • Hematologic / Rare Blood Disorders
  • Others
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Specialty Pharmacies
  • Online & Retail Channels
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biosimilars Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Biosimilars Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2025 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
  • 4.4. Monoclonal Antibodies (mAbs)
    • 4.4.1. Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.5. Growth Factors & Hematopoietic Agents
    • 4.5.1. Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.6. Insulin & Analogues
    • 4.6.1. Insulin & Analogues Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.7. Osteoporosis / Bone Metabolism Agents
    • 4.7.1. Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Biosimilars Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
  • 5.4. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
    • 5.4.1. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.5. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
    • 5.5.1. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.6. Diabetes Mellitus (Type 1 & Type 2)
    • 5.6.1. Diabetes Mellitus (Type 1 & Type 2) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.7. Ophthalmic Disorders (Wet AMD, DME, RVO)
    • 5.7.1. Ophthalmic Disorders (Wet AMD, DME, RVO) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.8. Hematologic / Rare Blood Disorders
    • 5.8.1. Hematologic / Rare Blood Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.9. Others
    • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Biosimilars Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2025 & 2033
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5. Specialty Pharmacies
    • 6.5.1. Specialty Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6. Online & Retail Channels
    • 6.6.1. Online & Retail Channels Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Biosimilars Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Biosimilars Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Type Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Type Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Type Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Type Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Type Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Type Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Type Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Type Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Type Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Type Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Type Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Type Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Type Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Type Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Type Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Type Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Type Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Type Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Type Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Type Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Type Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Type Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Type Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Amgen Inc
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. F Hoffman-La Roche Ltd.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sandoz International GmbH
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Dr. Reddy's Laboratories Ltd.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Teva Pharmaceutical Industries Ltd.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Samsung Biopis
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Biocon
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Viatris Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Celltrion Healthcare Co., Ltd.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. AbbVie Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List ofabbreviations
  • Table 3 Global biosimilars market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 5 Global biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 6 Global biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 7 North America biosimilars market, by country, 2021 - 2033 (USD Billion)
  • Table 8 North America biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 9 North America biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 10 North America biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 11 US biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 12 US biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 13 US biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 14 Canada biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 15 Canada biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 16 Canada biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 17 Mexico biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 18 Mexico biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 19 Mexico biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 20 Europe biosimilars market, by country, 2021 - 2033 (USD Billion)
  • Table 21 Europe biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 22 Europe biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 23 Europe biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 24 UK biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 25 UK biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 26 UK biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 27 Germany biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 28 Germany biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 29 Germany biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 30 France biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 31 France biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 32 France biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 33 Italy biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 34 Italy biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 35 Italy biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 36 Spain biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 37 Spain biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 38 Spain biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 39 Norway biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 40 Norway biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 41 Norway biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 42 Denmark biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 43 Denmark biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 44 Denmark biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 45 Sweden biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 46 Sweden biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 47 Sweden biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 48 Asia Pacific biosimilars market, by country, 2021 - 2033 (USD Billion)
  • Table 49 Asia Pacific biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 50 Asia Pacific biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 51 Asia Pacific biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 52 Japan biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 53 Japan biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 54 Japan biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 55 China biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 56 China biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 57 China biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 58 India biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 59 India biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 60 India biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 61 Australia biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 62 Australia biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 63 Australia biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 64 South Korea biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 65 South Korea biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 66 South Korea biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 67 Thailand biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 68 Thailand biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 69 Thailand biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 70 Latin America biosimilars market, by country, 2021 - 2033 (USD Billion)
  • Table 71 Latin America biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 72 Latin America biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 73 Latin America biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 74 Brazil biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 75 Brazil biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 76 Brazil biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 77 Argentina biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 78 Argentina biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 79 Argentina biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 80 Middle East & Africa biosimilars market, by country, 2021 - 2033 (USD Billion)
  • Table 81 Middle East & Africa biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 82 Middle East & Africa biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 83 Middle East & Africa biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 84 South Africa biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 85 South Africa biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 86 South Africa biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 87 Saudi Arabia biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 88 Saudi Arabia biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 89 Saudi Arabia biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 90 UAE biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 91 UAE biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 92 UAE biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 93 Kuwait biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 94 Kuwait biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 95 Kuwait biosimilars market, by end use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Biosimilars market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Billion)
  • Fig. 10 Competitive landscape
  • Fig. 11 Biosimilars market dynamics
  • Fig. 12 Biosimilars market: Porter's five forces analysis
  • Fig. 13 Biosimilars market: PESTLE analysis
  • Fig. 14 Drug Class market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 15 Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 16 Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 17 Insulin & Analogues Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 18 Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 19 Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 20 Indication market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 21 Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 22 Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 23 Diabetes Mellitus (Type 1 & Type 2) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 24 Ophthalmic Disorders (Wet AMD, DME, RVO) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 25 Hematologic / Rare Blood Disorders market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 26 Others market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 27 End Use market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 28 Hospitals market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 29 Specialty Pharmacies market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 30 Online & Retail Channels market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 31 Biosimilars market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 40 Europe biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 45 France country dynamics
  • Fig. 46 France biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain biosimilars market, 2021 - 2033 (USD Billion)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 57 Asia Pacific biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 60 China country dynamics
  • Fig. 61 China biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 62 India country dynamics
  • Fig. 63 India biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 70 Latin America biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 75 MEA biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework